
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is well-positioned for strong growth potential in the future with its innovative surgical robotic systems for minimally invasive urologic surgery. The company has achieved strong sales growth in recent quarters, led by its domestic capital placements and strong procedure growth rates. Additionally, the company's prostate cancer study is enrolling ahead of schedule, which could open up a new market opportunity for the company. While there may be some short-term concerns regarding softer handpiece sales and pricing pressure, the company's strong pipeline and potential for penetration into international markets provide a positive outlook for its stock in the long run.
Bears say
PROCEPT BioRobotics is facing several challenges, including steep financial ramps to meet its guidance, increasing competition in the BPH surgical market, and uncertainty around the shift in handpiece purchasing patterns. Additionally, the company's decision to eliminate bulk discounts could negatively impact revenue in the short term. However, the company's innovative technology and potential for expansion in the BPH market make it a long-term growth opportunity. With a heavily discounted valuation and tomorrow's Investor Day expected to provide more insights, the stock remains a volatile but attractive long-term investment opportunity.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares